Tumor	B-cell_type
cells	I-cell_type
regulate	O
the	O
lytic	O
activity	O
of	O
tumor-specific	B-cell_type
cytotoxic	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
by	O
modulating	O
the	O
inhibitory	O
natural	O
killer	O
receptor	O
function	O
.	O

Tumor-infiltrating	B-cell_type
p58+	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
a	O
renal	O
tumor	O
were	O
specifically	O
expanded	O
in	O
response	O
to	O
tumor	O
cell	O
stimulation	O
and	O
cloned	O
.	O

These	O
p58+	B-cell_type
T	I-cell_type
cells	I-cell_type
were	O
found	O
to	O
express	O
a	O
memory	B-cell_type
phenotype	I-cell_type
and	O
corresponded	O
to	O
clonal	O
TCRBV3	O
T-cell	O
expansion	O
.	O

Functionally	O
,	O
p58	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CTLs	I-cell_type
displayed	O
a	O
low	O
lytic	O
activity	O
for	O
HLA-A2	B-cell_type
tumor	I-cell_type
and	I-cell_type
normal	I-cell_type
cells	I-cell_type
.	O

However	O
,	O
this	O
lytic	O
activity	O
was	O
significantly	O
increased	O
after	O
blockade	O
of	O
p58	B-protein
with	O
specific	O
monoclonal	B-protein
antibodies	I-protein
.	O

Interestingly	O
,	O
we	O
demonstrated	O
that	O
stimulation	O
by	O
tumor	B-cell_type
cells	I-cell_type
was	O
required	O
to	O
trigger	O
the	O
inhibitory	O
effect	O
of	O
p58	B-protein
on	O
the	O
lytic	O
activity	O
of	O
antigen-specific	B-cell_type
CTLs	I-cell_type
and	O
that	O
stimulation	O
of	O
the	O
inhibitory	O
function	O
of	O
p58	B-protein
by	O
tumor	B-cell_type
cells	I-cell_type
correlated	O
with	O
an	O
inhibition	O
of	O
nuclear	O
factor-kappaB	O
activation	O
in	O
p58+	B-cell_type
tumor-specific	I-cell_type
CTLS	I-cell_type
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
61	NULL
,	NULL
3240-3244	NULL
,	NULL
April	NULL
15	NULL
,	NULL
2001	NULL
]	NULL
Advances	NULL
in	NULL
Brief	NULL
Tumor	NULL
Cells	NULL
Regulate	NULL
the	NULL
Lytic	NULL
Activity	NULL
of	NULL
Tumor-specific	NULL
Cytotoxic	NULL
T	NULL
Lymphocytes	NULL
by	NULL
Modulating	NULL
the	NULL
Inhibitory	NULL
Natural	NULL
Killer	NULL
Receptor	NULL
Function	NULL
'	NULL
Asma	NULL
Gati	NULL
,	NULL
Nadia	NULL
Guerra	NULL
,	NULL
Julien	NULL
Giron-Michel	NULL
,	NULL
Bruno	NULL
Azzarone	NULL
,	NULL
Eric	NULL
Angevin	NULL
,	NULL
Alessandro	NULL
Moretta	NULL
,	NULL
Salem	NULL
Chouaib	NULL
,	NULL
and	NULL
Anne	NULL
INSERM	NULL
U487	NULL
,	NULL
Institut	NULL
Fédératif	NULL
de	NULL
Recherche	NULL
(	NULL
IFR	NULL
54	NULL
)	NULL
[	NULL
A.	NULL
G.	NULL
,	NULL
N.	NULL
G.	NULL
,	NULL
S.C.	NULL
,	NULL
A.	NULL
C.	NULL
]	NULL
,	NULL
Unité	NULL
d'Immunologie	NULL
Clinique	NULL
[	NULL
E	NULL
.	NULL

A	NULL
.	NULL
]	NULL

,	NULL
Institut	NULL
Gustave	NULL
Roussy	NULL
,	NULL
94805	NULL
Villejuif	NULL
,	NULL
France	NULL
;	NULL
INSERM	NULL
U5O8	NULL
,	NULL
Hopital	NULL
Paul	NULL
Brousse	NULL
,	NULL
94805	NULL
Villejuif	NULL
,	NULL
France	NULL
[	NULL
J.	NULL
G-M.	NULL
,	NULL
B	NULL
.	NULL

A	NULL
.	NULL
]	NULL

;	NULL
and	NULL
Dipartimento	NULL
di	NULL
Medicina	NULL
Sperimentale	NULL
,	NULL
Universita	NULL
di	NULL
Genova	NULL
,	NULL
16132	NULL
Genova	NULL
,	NULL
Italy	NULL
[	NULL
A.	NULL
M.	NULL
]	NULL
Abstract	NULL
Tumor-infiltrating	NULL
p58*	NULL
T	NULL
cells	NULL
from	NULL
a	NULL
renal	NULL
tumor	NULL
were	NULL
specifically	NULL
expanded	NULL
in	NULL
response	NULL
to	NULL
tumor	NULL
cell	NULL
stimulation	NULL
and	NULL
cloned	NULL
.	NULL

These	NULL
p58*	NULL
T	NULL
cells	NULL
were	NULL
found	NULL
to	NULL
express	NULL
a	NULL
memory	NULL
phenotype	NULL
and	NULL
corresponded	NULL
to	NULL
clonal	NULL
TCRBV3	NULL
T-cell	NULL
expansion	NULL
.	NULL

Functionally	NULL
,	NULL
p58*	NULL
CTLs	NULL
displayed	NULL
a	NULL
low	NULL
lytic	NULL
activity	NULL
for	NULL
HLA-A2	NULL
tumor	NULL
and	NULL
normal	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
this	NULL
lytic	NULL
activity	NULL
was	NULL
significantly	NULL
increased	NULL
after	NULL
blockade	NULL
of	NULL
p58	NULL
with	NULL
specific	NULL
monoclonal	NULL
antibodies	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
stimulation	NULL
by	NULL
tumor	NULL
cells	NULL
was	NULL
required	NULL
to	NULL
trigger	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
p58	NULL
on	NULL
the	NULL
lytic	NULL
activity	NULL
of	NULL
antigen-specific	NULL
CTLs	NULL
and	NULL
that	NULL
stimulation	NULL
of	NULL
the	NULL
inhibitory	NULL
function	NULL
of	NULL
p58	NULL
by	NULL
tumor	NULL
cells	NULL
correlated	NULL
with	NULL
an	NULL
inhibition	NULL
of	NULL
nuclear	NULL
activation	NULL
in	NULL
p58*	NULL
tumor-specific	NULL
CTLs	NULL
.	NULL

Introduction	NULL
RCC	NULL
,	NULL
like	NULL
melanoma	NULL
,	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
a	NULL
potentially	NULL
immunogeneic	NULL
tumor	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
durable	NULL
tumoral	NULL
responses	NULL
were	NULL
obtained	NULL
after	NULL
IL-2	NULL
treatment	NULL
in	NULL
15-20	NULL
%	NULL
of	NULL
metastatic	NULL
patients	NULL
,	NULL
some	NULL
of	NULL
them	NULL
resulting	NULL
from	NULL
elicitation	NULL
of	NULL
T-cell	NULL
responses	NULL
(	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
large	NULL
CD3	NULL
infiltrate	NULL
,	NULL
it	NULL
is	NULL
difficult	NULL
to	NULL
generate	NULL
stable	NULL
tumor-specific	NULL
cytotoxic	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
's	NULL
,	NULL
and	NULL
the	NULL
rare	NULL
specific	NULL
CTLs	NULL
described	NULL
in	NULL
this	NULL
model	NULL
displayed	NULL
functional	NULL
alterations	NULL
that	NULL
resulted	NULL
in	NULL
marginal	NULL
lytic	NULL
potential	NULL
as	NULL
well	NULL
as	NULL
low	NULL
proliferation	NULL
efficiency	NULL
(	NULL
2	NULL
)	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
understand	NULL
the	NULL
alteration	NULL
of	NULL
in	NULL
sits	NULL
amplified	NULL
T-cell	NULL
proliferative	NULL
and	NULL
cytotoxic	NULL
responses	NULL
in	NULL
vifro	NULL
,	NULL
we	NULL
showed	NULL
previously	NULL
that	NULL
expression	NULL
of	NULL
inhibitory	NULL
NK-Rs	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
local	NULL
immune	NULL
suppression	NULL
detected	NULL
in	NULL
RCC	NULL
(	NULL
3	NULL
)	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
the	NULL
NK-R	NULL
family	NULL
specific	NULL
for	NULL
HLA-I	NULL
molecules	NULL
and	NULL
the	NULL
characterization	NULL
of	NULL
these	NULL
related	NULL
inhibitory	NULL
(	NULL
KIR	NULL
)	NULL
and	NULL
activatory	NULL
(	NULL
KAR	NULL
)	NULL
receptors	NULL
allowed	NULL
a	NULL
better	NULL
understanding	NULL
of	NULL
the	NULL
mechanisms	NULL
regulating	NULL
target	NULL
cell	NULL
recognition	NULL
as	NULL
well	NULL
as	NULL
NK	NULL
and	NULL
T-cell	NULL
activation	NULL
(	NULL
4	NULL
)	NULL
.	NULL

KIRs	NULL
have	NULL
also	NULL
been	NULL
detected	NULL
on	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
from	NULL
healthy	NULL
donors	NULL
with	NULL
a	NULL
selective	NULL
expression	NULL
on	NULL
minor	NULL
T-cell	NULL
subsets	NULL
,	NULL
mostly	NULL
of	NULL
the	NULL
CD8	NULL
*	NULL
,	NULL
CD28~	NULL
,	NULL
CD4SRO*	NULL
memory	NULL
phenotype	NULL
(	NULL
5	NULL
)	NULL
.	NULL

It	NULL
is	NULL
established	NULL
that	NULL
KIR	NULL
engagement	NULL
also	NULL
leads	NULL
to	NULL
inhibition	NULL
of	NULL
T-cell	NULL
functions	NULL
including	NULL
TCR-mediated	NULL
cytolytic	NULL
activity	NULL
and	NULL
lymphokine	NULL
production	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

We	NULL
previously	NULL
saw	NULL
evidence	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
particular	NULL
KIRs	NULL
(	NULL
p58	NULL
receptors	NULL
specific	NULL
for	NULL
HLA-C	NULL
molecules	NULL
)	NULL
by	NULL
Received	NULL
1/21/01	NULL
;	NULL
accepted	NULL
2/21/01	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
awarded	NULL
by	NULL
INSERM	NULL
and	NULL
Grant	NULL
ARC	NULL
9702	NULL
(	NULL
to	NULL
A.	NULL
C.	NULL
)	NULL
from	NULL
the	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Unité	NULL
INSERM	NULL
U487	NULL
Cytokines	NULL
et	NULL
Immunologie	NULL
des	NULL
Tumeurs	NULL
humaines	NULL
,	NULL
Institut	NULL
Gustave	NULL
Roussy	NULL
,	NULL
PR1	NULL
,	NULL
39	NULL
rue	NULL
Camille	NULL
Desmoulins	NULL
,	NULL
F-94805	NULL
Villejuif	NULL
,	NULL
France	NULL
.	NULL

Phone	NULL
:	NULL
33/1	NULL
42-11-50-36	NULL
;	NULL
Fax	NULL
:	NULL
33/1	NULL
42-11-52-88	NULL
;	NULL
E-mail	NULL
:	NULL
caignard	NULL
@	NULL
igr.fr	NULL
.	NULL

°	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
RCC	NULL
,	NULL
renal	NULL
cell	NULL
carcinoma	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
NK	NULL
,	NULL
natural	NULL
killer	NULL
;	NULL
NK-R	NULL
,	NULL
NK	NULL
receptor	NULL
;	NULL
TIL	NULL
,	NULL
tumor-infiltrating	NULL
lymphocyte	NULL
;	NULL
KIR	NULL
,	NULL
killer	NULL
inhibitory	NULL
receptor	NULL
;	NULL
PBL	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocyte	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
MLTC	NULL
,	NULL
mixed	NULL
lymphocyte	NULL
tumor	NULL
cell	NULL
culture	NULL
;	NULL
TCR	NULL
,	NULL
T-cell	NULL
receptor	NULL
;	NULL
NF-KB	NULL
,	NULL
nuclear	NULL
factor-kB	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
.	NULL

significant	NULL
subsets	NULL
of	NULL
TILs	NULL
in	NULL
most	NULL
RCCs	NULL
.	NULL

Among	NULL
the	NULL
tumors	NULL
studied	NULL
,	NULL
we	NULL
have	NULL
characterized	NULL
these	NULL
particular	NULL
KIR	NULL
*	NULL
T	NULL
cells	NULL
as	NULL
tumor-specific	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
which	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
NK-R	NULL
(	NULL
3	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
identified	NULL
a	NULL
subpopulation	NULL
of	NULL
p58	NULL
*	NULL
T	NULL
cells	NULL
detectable	NULL
at	NULL
the	NULL
tumor	NULL
site	NULL
and	NULL
that	NULL
corresponded	NULL
to	NULL
potentially	NULL
autoreactive	NULL
T	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
further	NULL
show	NULL
here	NULL
that	NULL
stimulation	NULL
by	NULL
tumor	NULL
cells	NULL
is	NULL
a	NULL
prerequisite	NULL
for	NULL
the	NULL
functional	NULL
inhibitory	NULL
effect	NULL
of	NULL
the	NULL
KIR	NULL
.	NULL

Tumor	NULL
cells	NULL
presumably	NULL
induce	NULL
the	NULL
recruitment	NULL
of	NULL
KIR	NULL
*	NULL
T	NULL
cells	NULL
reactive	NULL
to	NULL
self	NULL
antigens	NULL
at	NULL
the	NULL
tumor	NULL
site	NULL
and	NULL
control	NULL
their	NULL
lytic	NULL
activity	NULL
by	NULL
regulating	NULL
the	NULL
KIR	NULL
inhibitory	NULL
function	NULL
as	NULL
well	NULL
.	NULL

The	NULL
present	NULL
studies	NULL
point	NULL
to	NULL
a	NULL
particular	NULL
regulation	NULL
of	NULL
the	NULL
KIR	NULL
functionality	NULL
expressed	NULL
on	NULL
antigen-specific	NULL
p58	NULL
*	NULL
T	NULL
cells	NULL
by	NULL
autologous	NULL
renal	NULL
carcinoma	NULL
tumor	NULL
cells	NULL
and	NULL
reveal	NULL
a	NULL
new	NULL
mechanism	NULL
of	NULL
tumor	NULL
escape	NULL
to	NULL
the	NULL
host	NULL
T	NULL
cell-specific	NULL
immune	NULL
response	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Establishment	NULL
and	NULL
Culture	NULL
of	NULL
Tumor	NULL
Cell	NULL
Lines	NULL
.	NULL

The	NULL
autologous	NULL
tumor	NULL
cell	NULL
lines	NULL
were	NULL
derived	NULL
from	NULL
the	NULL
primary	NULL
tumor	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
total	NULL
cell	NULL
suspensions	NULL
were	NULL
centrifuged	NULL
onto	NULL
Ficoll	NULL
Hypaque	NULL
to	NULL
eliminate	NULL
dead	NULL
cells	NULL
,	NULL
and	NULL
viable	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
specific	NULL
culture	NULL
medium	NULL
to	NULL
amplify	NULL
tumor	NULL
cells	NULL
and	NULL
TILs	NULL
.	NULL

For	NULL
tumor	NULL
cells	NULL
,	NULL
DMEM/HAM	NULL
F-12	NULL
supplemented	NULL
with	NULL
1	NULL
%	NULL
glutamine	NULL
,	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
and	NULL
2	NULL
%	NULL
Ultroser	NULL
G	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
,	NULL
Paisley	NULL
,	NULL
Scotland	NULL
)	NULL
was	NULL
used	NULL
as	NULL
complete	NULL
medium	NULL
.	NULL

A	NULL
permanent	NULL
tumor	NULL
cell	NULL
line	NULL
was	NULL
derived	NULL
from	NULL
patient	NULL
VM	NULL
that	NULL
was	NULL
genotyped	NULL
as	NULL
HLA-A2	NULL
,	NULL
A26	NULL
,	NULL
BO4	NULL
,	NULL
B44	NULL
,	NULL
CwO05	NULL
,	NULL
Cw	NULL
~	NULL
.	NULL

Confluent	NULL
culture	NULL
dishes	NULL
were	NULL
treated	NULL
by	NULL
EDTA/trypsin	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
subcultured	NULL
.	NULL

Immunofluorescence	NULL
Analysis	NULL
.	NULL

The	NULL
phenotypes	NULL
of	NULL
TILs	NULL
and	NULL
PBLs	NULL
were	NULL
analyzed	NULL
by	NULL
indirect	NULL
two-color	NULL
fluorescence	NULL
.	NULL

Cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
first	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
with	NULL
conjugated	NULL
mAbs	NULL
:	NULL
EB6-PE	NULL
(	NULL
anti-p58.1	NULL
,	NULL
IgG1	NULL
)	NULL
,	NULL
GL183-PE	NULL
(	NULL
anti-p58.2	NULL
,	NULL
IgG1	NULL
)	NULL
,	NULL
CH92-PE	NULL
(	NULL
anti-BV3TCR	NULL
,	NULL
IgM	NULL
)	NULL
,	NULL
CD3-FITC	NULL
,	NULL
CD56-PECy5	NULL
,	NULL
and	NULL
CD8-FITC	NULL
purchased	NULL
from	NULL
Immunotech	NULL
(	NULL
Marseille	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Analysis	NULL
was	NULL
performed	NULL
on	NULL
5000	NULL
gated	NULL
TILs	NULL
(	NULL
appearing	NULL
in	NULL
forward	NULL
scatter/side	NULL
scatter	NULL
as	NULL
small	NULL
lymphocytes	NULL
comparable	NULL
with	NULL
PBLs	NULL
)	NULL
after	NULL
exclusion	NULL
of	NULL
dead	NULL
cells	NULL
and	NULL
debris	NULL
.	NULL

Background	NULL
levels	NULL
were	NULL
measured	NULL
using	NULL
isotypic	NULL
controls	NULL
.	NULL

Analysis	NULL
was	NULL
done	NULL
on	NULL
a	NULL
FACS-Sort	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Pont	NULL
de	NULL
Claix	NULL
,	NULL
France	NULL
)	NULL
using	NULL
Cell	NULL
Quest	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Compensation	NULL
was	NULL
set	NULL
up	NULL
with	NULL
single	NULL
stained	NULL
samples	NULL
.	NULL

Derivation	NULL
of	NULL
p58*	NULL
,	NULL
p58~	NULL
T-Cell	NULL
Lines	NULL
and	NULL
CTLs	NULL
.	NULL

TILs	NULL
were	NULL
stimulated	NULL
for	NULL
2	NULL
weeks	NULL
in	NULL
MLTC	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
30	NULL
units/ml	NULL
IL-2	NULL
before	NULL
positive	NULL
selection	NULL
of	NULL
p58	NULL
*	NULL
T	NULL
cells	NULL
using	NULL
anti-p58.2	NULL
mAb	NULL
(	NULL
GL183	NULL
)	NULL
and	NULL
immunomagnetic	NULL
beads	NULL
(	NULL
Dynal	NULL
,	NULL
Campiégne	NULL
,	NULL
France	NULL
)	NULL
.	NULL

After	NULL
immunoselection	NULL
,	NULL
p58*	NULL
and	NULL
p58~	NULL
T-cell	NULL
subsets	NULL
were	NULL
expanded	NULL
(	NULL
3	NULL
X	NULL
10°	NULL
cells/well	NULL
)	NULL
on	NULL
irradiated	NULL
allogeneic	NULL
feeder	NULL
cells	NULL
(	NULL
7	NULL
X	NULL
10*	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
+	NULL
3	NULL
X	NULL
10+	NULL
``	NULL
LAZ	NULL
509	NULL
cells/well	NULL
)	NULL
and	NULL
of	NULL
irradiated	NULL
autologous	NULL
tumor	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cells/well	NULL
)	NULL
.	NULL

The	NULL
p58*	NULL
T-cell	NULL
line	NULL
was	NULL
cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
0.3-1	NULL
cell/well	NULL
using	NULL
the	NULL
above	NULL
feeder	NULL
cell	NULL
conditions	NULL
.	NULL

For	NULL
regulation	NULL
of	NULL
KIR	NULL
function	NULL
,	NULL
CTLs	NULL
were	NULL
cultured	NULL
on	NULL
irradiated	NULL
LAZ509	NULL
cells	NULL
(	NULL
HLA-A2	NULL
,	NULL
Cw6	NULL
,	NULL
Cw12	NULL
)	NULL
alone	NULL
(	NULL
3	NULL
X	NULL
10*	NULL
cells/well	NULL
)	NULL
or	NULL
in	NULL
presence	NULL
of	NULL
3	NULL
X	NULL
10°	NULL
tumor	NULL
cells/well	NULL
for	NULL
6-8	NULL
days	NULL
.	NULL

Assay	NULL
for	NULL
Cytolytic	NULL
Activity	NULL
.	NULL

The	NULL
cytolytic	NULL
activity	NULL
of	NULL
T-cell	NULL
lines	NULL
and	NULL
clones	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
4-h	NULL
°'Cr	NULL
release	NULL
assay	NULL
,	NULL
against	NULL
autologous	NULL
PHA	NULL
blasts	NULL
,	NULL
autologous	NULL
tumor	NULL
cells	NULL
(	NULL
VM	NULL
)	NULL
,	NULL
allogeneic	NULL
tumor	NULL
cell	NULL
lines	NULL
(	NULL
LR	NULL
,	NULL
DM	NULL
,	NULL
GE	NULL
,	NULL
Caje	NULL
,	NULL
and	NULL
CS	NULL
)	NULL
,	NULL
and	NULL
EBV-transformed	NULL
B	NULL
cells	NULL
(	NULL
LAZ509	NULL
and	NULL
LCL	NULL
GE	NULL
)	NULL
as	NULL
3240	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

SPECIFIC	NULL
T-CELL	NULL
RESPONSE	NULL
IN	NULL
RENAL	NULL
TUMORS	NULL
described	NULL
previously	NULL
(	NULL
8	NULL
)	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
mAbs	NULL
11PB6	NULL
and	NULL
EB6	NULL
(	NULL
anti-p58.1	NULL
)	NULL
,	NULL
GL183	NULL
(	NULL
anti-p58.2	NULL
)	NULL
,	NULL
B1.23.2	NULL
(	NULL
anti-HLA-B/C	NULL
,	NULL
IgG2a	NULL
)	NULL
,	NULL
Z27	NULL
(	NULL
anti-p70	NULL
,	NULL
IgG1	NULL
)	NULL
,	NULL
and	NULL
UCHT1	NULL
(	NULL
anti-CD3	NULL
,	NULL
IgG1	NULL
)	NULL
were	NULL
added	NULL
at	NULL
predefined	NULL
saturating	NULL
concentrations	NULL
at	NULL
the	NULL
onset	NULL
of	NULL
the	NULL
cytolytic	NULL
assay	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
specific	NULL
lysis	NULL
at	NULL
the	NULL
indicated	NULL
E	NULL
:	NULL
T	NULL
cell	NULL
ratio	NULL
.	NULL

The	NULL
cytolytic	NULL
activity	NULL
of	NULL
T-cell	NULL
lines	NULL
was	NULL
also	NULL
assessed	NULL
in	NULL
a	NULL
CD3-redirected	NULL
lysis	NULL
assay	NULL
using	NULL
P815	NULL
mastocytoma	NULL
mouse	NULL
cells	NULL
.	NULL

Briefly	NULL
,	NULL
*'Cr-labeled	NULL
P815	NULL
(	NULL
3	NULL
X	NULL
10°	NULL
)	NULL
cells	NULL
coated	NULL
with	NULL
anti-CD3e	NULL
(	NULL
1-100	NULL
ng/ml	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
serial	NULL
dilutions	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
ranging	NULL
from	NULL
10:1	NULL
to	NULL
2:1	NULL
)	NULL
.	NULL

CD3-redirected	NULL
lysis	NULL
of	NULL
labeled	NULL
P815	NULL
cells	NULL
was	NULL
modulated	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
anti-KIR	NULL
mAbs	NULL
(	NULL
4	NULL
ug/well	NULL
)	NULL
.	NULL

Results	NULL
obtained	NULL
in	NULL
independent	NULL
experiments	NULL
were	NULL
statistically	NULL
analyzed	NULL
using	NULL
the	NULL
Fisher	NULL
test	NULL
.	NULL

TCRBV	NULL
Gene	NULL
Segment	NULL
Usage	NULL
and	NULL
Sequencing	NULL
of	NULL
TCR	NULL
Expressed	NULL
by	NULL
CTLs	NULL
.	NULL

TCRBV	NULL
gene	NULL
segment	NULL
usage	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
semiquantitative	NULL
PCR	NULL
analysis	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
total	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
T-cell	NULL
lines	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
,	NULL
using	NULL
a	NULL
modified	NULL
guanidinium	NULL
thiocyanate	NULL
phenol/chloroform	NULL
method	NULL
(	NULL
Trizol	NULL
;	NULL
Eurobio	NULL
,	NULL
Les	NULL
Ulis	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Amplification	NULL
of	NULL
cDNA	NULL
was	NULL
performed	NULL
over	NULL
30	NULL
cycles	NULL
with	NULL
the	NULL
5	NULL
'	NULL
sense	NULL
primers	NULL
specific	NULL
for	NULL
the	NULL
24	NULL
TCRBV	NULL
subfamilies	NULL
and	NULL
one	NULL
3	NULL
'	NULL
antisense	NULL
TCRBC-specific	NULL
primer	NULL
,	NULL
and	NULL
amplimers	NULL
were	NULL
detected	NULL
after	NULL
electrophoresis	NULL
on	NULL
agarose	NULL
gel	NULL
.	NULL

TCRBV3-BC	NULL
PCR	NULL
products	NULL
derived	NULL
from	NULL
pS8*	NULL
CTLs	NULL
were	NULL
purified	NULL
using	NULL
the	NULL
Qiagene	NULL
columns	NULL
(	NULL
Qiaquick	NULL
PCR	NULL
purification	NULL
kit	NULL
;	NULL
Hilden	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
sequenced	NULL
using	NULL
ABI	NULL
Prism	NULL
Big	NULL
Dye	NULL
sequencing	NULL
Ready	NULL
Reactions	NULL
kits	NULL
before	NULL
electrophoresis	NULL
on	NULL
an	NULL
ABI	NULL
sequencer	NULL
(	NULL
Applied	NULL
Biosystem	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Confocal	NULL
Microscopy	NULL
Analysis	NULL
.	NULL

Transcription	NULL
factor	NULL
NF-kB	NULL
was	NULL
detected	NULL
using	NULL
1	NULL
ug/ml	NULL
of	NULL
the	NULL
rabbit	NULL
polyclonal	NULL
purified	NULL
IgG	NULL
anti-NF-B	NULL
p65	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
incubation	NULL
with	NULL
Alexa	NULL
Fluor	NULL
488	NULL
GAR	NULL
(	NULL
Molecular	NULL
Probes	NULL
)	NULL
.	NULL

Nuclei	NULL
were	NULL
stained	NULL
using	NULL
propidium	NULL
iodide	NULL
(	NULL
red	NULL
staining	NULL
)	NULL
.	NULL

Stained	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
,	NULL
cytocentrifuged	NULL
in	NULL
a	NULL
cytospin	NULL
3	NULL
(	NULL
Shandon	NULL
,	NULL
Pittsburg	NULL
,	NULL
PA	NULL
)	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
laser	NULL
scanning	NULL
confocal	NULL
microscopy	NULL
using	NULL
a	NULL
Leica	NULL
TCS	NULL
Confocal	NULL
System	NULL
(	NULL
Wetzler	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Results	NULL
Clonal	NULL
p58*	NULL
T	NULL
Cells	NULL
Expressing	NULL
a	NULL
Unique	NULL
TCR	NULL
Are	NULL
Detected	NULL
at	NULL
the	NULL
Tumor	NULL
Site	NULL
and	NULL
Successfully	NULL
Expanded	NULL
in	NULL
Vitro	NULL
in	NULL
MLTC	NULL
.	NULL

Analysis	NULL
of	NULL
TILs	NULL
and	NULL
PBLs	NULL
from	NULL
RCC	NULL
patients	NULL
was	NULL
performed	NULL
by	NULL
double	NULL
color	NULL
immunofluorescence	NULL
using	NULL
conjugated	NULL
anti-p58	NULL
and	NULL
CD3	NULL
mAbs	NULL
to	NULL
measure	NULL
expression	NULL
of	NULL
p58	NULL
on	NULL
NK	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

From	NULL
dissociated	NULL
tumor	NULL
,	NULL
p58	NULL
*	NULL
T	NULL
cells	NULL
represented	NULL
9	NULL
%	NULL
of	NULL
the	NULL
CD3¢*	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
CD56	NULL
*/CD3~	NULL
NK	NULL
cells	NULL
constituted	NULL
9	NULL
%	NULL
of	NULL
the	NULL
TIL	NULL
population	NULL
,	NULL
and	NULL
2.5	NULL
%	NULL
were	NULL
p58~*	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

NK	NULL
receptor	NULL
p58	NULL
was	NULL
expressed	NULL
by	NULL
5	NULL
%	NULL
of	NULL
the	NULL
CD3	NULL
*	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
PBLs	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
7	NULL
%	NULL
of	NULL
blood	NULL
CD56	NULL
NK	NULL
cells	NULL
,	NULL
2	NULL
%	NULL
coexpressed	NULL
a	NULL
p58	NULL
receptor	NULL
.	NULL

After	NULL
stimulation	NULL
by	NULL
tumor	NULL
cells	NULL
in	NULL
MLTC	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
low	NULL
doses	NULL
of	NULL
IL-2	NULL
,	NULL
TILs	NULL
proliferated	NULL
(	NULL
two	NULL
to	NULL
four	NULL
times	NULL
)	NULL
mainly	NULL
from	NULL
the	NULL
CD8	NULL
subset	NULL
,	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
p58	NULL
~*	NULL
cells	NULL
was	NULL
maintained	NULL
reaching	NULL
10	NULL
%	NULL
of	NULL
the	NULL
CD3	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
PBLs	NULL
stimulated	NULL
by	NULL
autologous	NULL
tumor	NULL
cells	NULL
did	NULL
not	NULL
proliferate	NULL
and	NULL
remained	NULL
in	NULL
a	NULL
non-activated	NULL
state	NULL
with	NULL
a	NULL
significant	NULL
loss	NULL
of	NULL
CD56	NULL
expression	NULL
and	NULL
a	NULL
subsequent	NULL
decrease	NULL
in	NULL
p58	NULL
*/CD3+*	NULL
T-cell	NULL
subset	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

To	NULL
further	NULL
characterize	NULL
p58	NULL
*/CD3	NULL
*	NULL
T	NULL
cells	NULL
amplified	NULL
during	NULL
MLTC	NULL
from	NULL
TILs	NULL
,	NULL
p58	NULL
*	NULL
cells	NULL
were	NULL
immunoselected	NULL
and	NULL
expanded	NULL
in	NULL
vitro	NULL
.	NULL

As	NULL
described	NULL
previously	NULL
,	NULL
these	NULL
cells	NULL
express	NULL
CD56	NULL
and	NULL
CD45RO	NULL
but	NULL
not	NULL
CD28	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
p58	NULL
*	NULL
T	NULL
cells	NULL
displayed	NULL
a	NULL
very	NULL
restricted	NULL
TCR	NULL
repertoire	NULL
expressing	NULL
only	NULL
TCRBV3	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Using	NULL
specific	NULL
mAbs	NULL
,	NULL
double	NULL
color	NULL
immunofluorescence	NULL
analysis	NULL
was	NULL
performed	NULL
to	NULL
visualize	NULL
antigen-specific	NULL
p58	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
sifu	NULL
.	NULL

In	NULL
tumor	NULL
,	NULL
TCRBV3*	NULL
p58*	NULL
T	NULL
cells	NULL
corresponded	NULL
to	NULL
1	NULL
%	NULL
of	NULL
the	NULL
mononuclear	NULL
gated	NULL
cells	NULL
but	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
PBLs	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

Analysis	NULL
by	NULL
reverse	NULL
transcription-PCR	NULL
of	NULL
TCR	NULL
repertoire	NULL
using	NULL
a	NULL
panel	NULL
of	NULL
24	NULL
BV-specific	NULL
primers	NULL
confirmed	NULL
the	NULL
presence	NULL
of	NULL
unique	NULL
BV3	NULL
transcripts	NULL
in	NULL
p58	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
the	NULL
p58~	NULL
T-cell	NULL
line	NULL
displayed	NULL
a	NULL
polyclonal	NULL
TCR	NULL
repertoire	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
To	NULL
MLTC	NULL
TIL	NULL
C	NULL
o	NULL
o	NULL
PBL	NULL
B	NULL
CD8	NULL
p58	NULL
TCRBV3	NULL
CD45RO	NULL
CD28	NULL
Counts	NULL
0	NULL
Counts	NULL
94	NULL
t	NULL
T	NULL
T	NULL
t	NULL
on	NULL
oad	NULL
oe	NULL
as	NULL
TIL	NULL
PBL	NULL
TCRBV3	NULL
-	NULL
05	NULL
i	NULL
>	NULL
Lat	NULL
p58	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

A	NULL
,	NULL
detection	NULL
of	NULL
p58	NULL
``	NULL
NK	NULL
and	NULL
T	NULL
cells	NULL
in	NULL
TILs	NULL
and	NULL
PBLs	NULL
in	NULL
vivo	NULL
(	NULL
TO	NULL
)	NULL
and	NULL
after	NULL
in	NULL
vitro	NULL
stimulation	NULL
of	NULL
TILs	NULL
and	NULL
PBLs	NULL
by	NULL
autologous	NULL
tumor	NULL
cells	NULL
(	NULL
MLTC	NULL
)	NULL
.	NULL

B	NULL
,	NULL
phenotype	NULL
of	NULL
pS8*	NULL
T-cell	NULL
line	NULL
and	NULL
CTLs	NULL
.	NULL

C	NULL
,	NULL
detection	NULL
of	NULL
pS8*	NULL
TCRBV3	NULL
T	NULL
cells	NULL
in	NULL
sifu	NULL
.	NULL

p58	NULL
Receptor	NULL
Inhibits	NULL
the	NULL
CD3-mediated	NULL
Lysis	NULL
of	NULL
CTL	NULL
Clones	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
the	NULL
p58	NULL
receptor	NULL
interferes	NULL
with	NULL
the	NULL
lytic	NULL
activity	NULL
of	NULL
CTL	NULL
clones	NULL
,	NULL
blocking	NULL
experiments	NULL
with	NULL
specific	NULL
mAbs	NULL
were	NULL
per-formed	NULL
.	NULL

As	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
after	NULL
immunoselection	NULL
,	NULL
both	NULL
p58	NULL
*	NULL
and	NULL
p58	NULL
-	NULL
T-cell	NULL
subsets	NULL
were	NULL
found	NULL
to	NULL
display	NULL
low	NULL
levels	NULL
of	NULL
cytotoxic	NULL
activity	NULL
against	NULL
autologous	NULL
tumor	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
when	NULL
anti-HLA-BC	NULL
(	NULL
not	NULL
recognizing	NULL
HLA-A	NULL
molecules	NULL
)	NULL
or	NULL
anti-p58	NULL
mAbs	NULL
were	NULL
added	NULL
during	NULL
the	NULL
effector	NULL
phase	NULL
,	NULL
a	NULL
dramatic	NULL
increase	NULL
in	NULL
the	NULL
lysis	NULL
of	NULL
tumor	NULL
cells	NULL
by	NULL
p58	NULL
*	NULL
T	NULL
cells	NULL
but	NULL
not	NULL
by	NULL
p58	NULL
~	NULL
T	NULL
cells	NULL
was	NULL
observed	NULL
.	NULL

Using	NULL
limiting	NULL
dilution	NULL
,	NULL
from	NULL
the	NULL
selected	NULL
p58	NULL
*	NULL
T-cell	NULL
line	NULL
,	NULL
we	NULL
derived	NULL
12	NULL
proliferative	NULL
T-cell	NULL
clones	NULL
displaying	NULL
a	NULL
similar	NULL
lytic	NULL
potential	NULL
.	NULL

They	NULL
all	NULL
expressed	NULL
TCRBV3	NULL
chain	NULL
,	NULL
p58.1+*	NULL
and	NULL
p58.2*	NULL
receptors	NULL
.	NULL

Sequencing	NULL
of	NULL
TCRBV3	NULL
chain	NULL
in	NULL
three	NULL
TCRBV3	NULL
CTL	NULL
clones	NULL
revealed	NULL
an	NULL
identical	NULL
TCRBV3/BJ	NULL
1.2	NULL
rearrange-ment	NULL
,	NULL
indicating	NULL
that	NULL
they	NULL
derived	NULL
from	NULL
the	NULL
same	NULL
clone	NULL
,	NULL
and	NULL
CTL	NULL
2H7	NULL
was	NULL
further	NULL
used	NULL
as	NULL
a	NULL
representative	NULL
clone	NULL
.	NULL

Although	NULL
both	NULL
p58.1	NULL
and	NULL
pS58.2	NULL
receptors	NULL
were	NULL
expressed	NULL
by	NULL
p58	NULL
CTLs	NULL
,	NULL
tumor	NULL
cells	NULL
(	NULL
HLA-CwO05	NULL
,	NULL
Cw-	NULL
)	NULL
were	NULL
found	NULL
to	NULL
only	NULL
express	NULL
the	NULL
HLA-Cw4	NULL
supertype	NULL
,	NULL
the	NULL
ligand	NULL
for	NULL
p58.1	NULL
receptor	NULL
.	NULL

Accordingly	NULL
,	NULL
the	NULL
lytic	NULL
activity	NULL
of	NULL
CTL	NULL
2H7	NULL
against	NULL
autologous	NULL
tumor	NULL
cells	NULL
was	NULL
inhibited	NULL
by	NULL
anti-p58.1	NULL
or	NULL
anti	NULL
HLA-B/C	NULL
mAbs	NULL
added	NULL
during	NULL
the	NULL
effector	NULL
phase	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
functionality	NULL
of	NULL
p58	NULL
receptors	NULL
was	NULL
also	NULL
assessed	NULL
by	NULL
CD3-redirected	NULL
lysis	NULL
of	NULL
P815	NULL
murine	NULL
cells	NULL
.	NULL

These	NULL
assays	NULL
revealed	NULL
that	NULL
p58	NULL
CTLs	NULL
displayed	NULL
a	NULL
high	NULL
lytic	NULL
potential	NULL
because	NULL
limited	NULL
quantities	NULL
of	NULL
anti-CD3	NULL
immunoglobulin	NULL
(	NULL
1-10	NULL
ng/m	NULL
!	NULL
)	NULL

were	NULL
able	NULL
to	NULL
activate	NULL
the	NULL
lytic	NULL
machinery	NULL
.	NULL

3241	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

SPECIFIC	NULL
T-CELL	NULL
RESPONSE	NULL
IN	NULL
RENAL	NULL
TUMORS	NULL
-O-	NULL
p58+	NULL
cell	NULL
line	NULL
-	NULL
&	NULL
-p58-	NULL
cell	NULL
line	NULL
-	NULL
#	NULL
-	NULL
p58+cell	NULL
line+	NULL
anti	NULL
HLA-BC	NULL
-	NULL
&	NULL
-	NULL
p58-	NULL
cell	NULL
line+anti	NULL
HLA-BC	NULL
A	NULL
60	NULL
50	NULL
40	NULL
as	NULL
4	NULL
30	NULL
3	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

A	NULL
,	NULL
functional	NULL
analysis	NULL
of	NULL
pS8*	NULL
and	NULL
pS8~	NULL
20	NULL
T-cell	NULL
lines	NULL
.	NULL

Cytotoxic	NULL
activity	NULL
of	NULL
T-cell	NULL
lines	NULL
against	NULL
autologous	NULL
tumor	NULL
cells	NULL
was	NULL
tested	NULL
in	NULL
a	NULL
standard	NULL
chromium	NULL
release	NULL
assay	NULL
at	NULL
the	NULL
indicated	NULL
10	NULL
ratio	NULL
of	NULL
E	NULL
:	NULL
T	NULL
cells	NULL
.	NULL

Inhibition	NULL
of	NULL
the	NULL
lytic	NULL
activity	NULL
was	NULL
o	NULL
,	NULL
-	NULL
,	NULL
t	NULL
t	NULL
tested	NULL
after	NULL
incubation	NULL
of	NULL
the	NULL
cells	NULL
for	NULL
30	NULL
min	NULL
with	NULL
the	NULL
indicated	NULL
mAbs	NULL
before	NULL
the	NULL
test	NULL
.	NULL

B	NULL
,	NULL
lytic	NULL
activity	NULL
of	NULL
p58*	NULL
CTL	NULL
2H7	NULL
against	NULL
tumor	NULL
cells	NULL
(	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
10:1	NULL
and	NULL
5:1	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-p58.1	NULL
and	NULL
anti	NULL
HLA-BC	NULL
mAbs	NULL
.	NULL

C	NULL
,	NULL
CD3-redi-	NULL
__	NULL
8	NULL
rected	NULL
lysis	NULL
of	NULL
P815	NULL
cells	NULL
induced	NULL
by	NULL
CTL	NULL
2H7	NULL
was	NULL
generated	NULL
by	NULL
anti-CD3e	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-KIR	NULL
mAbs	NULL
.	NULL

30/1	NULL
60	NULL
50	NULL
4	NULL
40	NULL
{	NULL
30	NULL
4	NULL
20	NULL
4	NULL
10	NULL
4	NULL
Lysis	NULL
%	NULL
Engagement	NULL
of	NULL
p58.1	NULL
or	NULL
p58.2	NULL
receptor	NULL
by	NULL
specific	NULL
mAbs	NULL
inhibited	NULL
the	NULL
CD3-redirected	NULL
lysis	NULL
of	NULL
mouse	NULL
FeR	NULL
*	NULL
P815	NULL
cells	NULL
by	NULL
CTL	NULL
2H7	NULL
,	NULL
indicating	NULL
that	NULL
both	NULL
p58.1	NULL
and	NULL
p58.2	NULL
receptors	NULL
were	NULL
functional	NULL
and	NULL
inhibitory	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
these	NULL
tests	NULL
were	NULL
performed	NULL
using	NULL
serial	NULL
concentrations	NULL
of	NULL
anti-CD3	NULL
mAb	NULL
to	NULL
obtain	NULL
optimal	NULL
triggering	NULL
of	NULL
CD3	NULL
,	NULL
which	NULL
could	NULL
be	NULL
modulated	NULL
by	NULL
the	NULL
KIR	NULL
receptor	NULL
.	NULL

This	NULL
also	NULL
indicates	NULL
that	NULL
the	NULL
outcome	NULL
of	NULL
the	NULL
lysis	NULL
results	NULL
most	NULL
likely	NULL
from	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
balance	NULL
between	NULL
positive	NULL
(	NULL
CD3	NULL
)	NULL
and	NULL
negative	NULL
(	NULL
KIR	NULL
)	NULL
signals	NULL
.	NULL

p58*	NULL
T	NULL
Cells	NULL
Kill	NULL
Both	NULL
Normal	NULL
Autologous	NULL
Tumor	NULL
Cells	NULL
and	NULL
HLA-A2+*	NULL
Allogeneic	NULL
Tumor	NULL
Targets	NULL
.	NULL

The	NULL
lytic	NULL
activity	NULL
of	NULL
CTL	NULL
2H7	NULL
was	NULL
assessed	NULL
against	NULL
different	NULL
normal	NULL
and	NULL
tumor	NULL
cell	NULL
lines	NULL
by	NULL
cytotoxicity	NULL
assays	NULL
performed	NULL
in	NULL
presence	NULL
of	NULL
mAbs	NULL
to	NULL
block	NULL
p58	NULL
receptor	NULL
.	NULL

Data	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
indicate	NULL
that	NULL
CTL	NULL
2H7	NULL
efficiently	NULL
killed	NULL
autologous	NULL
normal	NULL
PHA	NULL
blasts	NULL
and	NULL
three	NULL
of	NULL
four	NULL
HLA-A2	NULL
renal	NULL
tumor	NULL
cell	NULL
lines	NULL
,	NULL
whereas	NULL
one	NULL
HLA-A2~	NULL
was	NULL
not	NULL
recognized	NULL
.	NULL

It	NULL
also	NULL
induced	NULL
the	NULL
lysis	NULL
of	NULL
HLA-A2	NULL
*	NULL
B-cell	NULL
lines	NULL
and	NULL
one	NULL
T	NULL
lymphoma	NULL
with	NULL
high	NULL
efficiency	NULL
.	NULL

Differences	NULL
in	NULL
lysis	NULL
of	NULL
HLA-A2*	NULL
tumor	NULL
cells	NULL
may	NULL
reflect	NULL
their	NULL
different	NULL
expression	NULL
levels	NULL
of	NULL
HLA-A2	NULL
and	NULL
HLA-C	NULL
alleles	NULL
that	NULL
control	NULL
,	NULL
respectively	NULL
,	NULL
the	NULL
positive	NULL
and	NULL
negative	NULL
signals	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
CTL	NULL
2H7	NULL
recognizes	NULL
a	NULL
ubiquitous	NULL
antigen	NULL
,	NULL
probably	NULL
presented	NULL
by	NULL
the	NULL
HLA-A2	NULL
molecule	NULL
,	NULL
and	NULL
most	NULL
likely	NULL
corresponds	NULL
to	NULL
an	NULL
autoreactive	NULL
T-cell	NULL
clone	NULL
functionally	NULL
regulated	NULL
by	NULL
a	NULL
powerful	NULL
p58	NULL
inhibitory	NULL
receptor	NULL
.	NULL

Tumor	NULL
Cells	NULL
Trigger	NULL
p58	NULL
Inhibitory	NULL
Function	NULL
and	NULL
Inhibit	NULL
NF-KB	NULL
Activation	NULL
in	NULL
Tumor-specific	NULL
CTLs	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
the	NULL
local	NULL
in	NULL
vivo	NULL
expansion	NULL
of	NULL
these	NULL
particular	NULL
CD3	NULL
*/p58*	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
tumor	NULL
cells	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
p58	NULL
*	NULL
antigen-specific	NULL
CTLs	NULL
.	NULL

We	NULL
showed	NULL
that	NULL
stimulation	NULL
of	NULL
CTL	NULL
2H7	NULL
with	NULL
irradiated	NULL
stimulating	NULL
LAZ509	NULL
cells	NULL
(	NULL
efficiently	NULL
recognized	NULL
by	NULL
CTL	NULL
2H7	NULL
)	NULL
alone	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
lytic	NULL
activity	NULL
of	NULL
this	NULL
clone	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
anti-p58.1	NULL
or	NULL
anti-BC	NULL
mAbs	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
tumor	NULL
cells	NULL
(	NULL
1	NULL
of	NULL
10	NULL
)	NULL
to	NULL
LAZ509	NULL
turned	NULL
on	NULL
the	NULL
inhibitory	NULL
function	NULL
of	NULL
KIR	NULL
and	NULL
resulted	NULL
in	NULL
an	NULL
abrogation	NULL
of	NULL
the	NULL
basal	NULL
lytic	NULL
activity	NULL
of	NULL
CTL	NULL
2H7	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

In	NULL
five	NULL
independent	NULL
CD3-redirected	NULL
lysis	NULL
experiments	NULL
,	NULL
anti-p58.1	NULL
mAb	NULL
did	NULL
not	NULL
significantly	NULL
affect	NULL
the	NULL
lysis	NULL
of	NULL
CD3-coated	NULL
P815	NULL
cells	NULL
by	NULL
LAZ509-stimulated	NULL
CTLs	NULL
(	NULL
P	NULL
>	NULL
0.05	NULL
)	NULL
,	NULL
whereas	NULL
it	NULL
significantly	NULL
decreased	NULL
their	NULL
lysis	NULL
by	NULL
CTLs	NULL
stimulated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
tumor	NULL
cells	NULL
(	NULL
P	NULL
=	NULL
0.0042	NULL
)	NULL
as	NULL
assessed	NULL
by	NULL
Fisher	NULL
test	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

It	NULL
should	NULL
also	NULL
be	NULL
noted	NULL
that	NULL
phenotypic	NULL
analysis	NULL
of	NULL
CTLs	NULL
stimulated	NULL
under	NULL
15/71	NULL
7M	NULL
C	NULL
CD3-redirected	NULL
lysis	NULL
60	NULL
cos	NULL
ignii	NULL
p58.1	NULL
50	NULL
&	NULL
CD3+anti	NULL
p58.1	NULL
HLA-BC	NULL
p58.2	NULL
MCD3+anti	NULL
p70	NULL
these	NULL
distinct	NULL
conditions	NULL
was	NULL
similar	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
p58	NULL
receptors	NULL
(	NULL
similar	NULL
mean	NULL
fluorescence	NULL
intensity	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
tumor	NULL
cells	NULL
does	NULL
not	NULL
involve	NULL
p58	NULL
receptor	NULL
expression	NULL
but	NULL
rather	NULL
its	NULL
function	NULL
.	NULL

Because	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
the	NULL
alteration	NULL
of	NULL
TIL	NULL
function	NULL
in	NULL
RCC	NULL
correlated	NULL
with	NULL
the	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
activation	NULL
(	NULL
10	NULL
)	NULL
,	NULL
we	NULL
therefore	NULL
asked	NULL
whether	NULL
under	NULL
our	NULL
experimental	NULL
condition	NULL
,	NULL
a	NULL
correlation	NULL
exists	NULL
between	NULL
KIR	NULL
inhibitory	NULL
function	NULL
and	NULL
NF-KB	NULL
activation	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
dramatic	NULL
decrease	NULL
of	NULL
NF-KB	NULL
in	NULL
CTLs	NULL
after	NULL
stimulation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
tumor	NULL
cells	NULL
that	NULL
paralleled	NULL
the	NULL
inhibitory	NULL
function	NULL
of	NULL
the	NULL
p58	NULL
receptor	NULL
.	NULL

Using	NULL
confocal	NULL
microscopy	NULL
,	NULL
we	NULL
show	NULL
the	NULL
nuclear	NULL
localization	NULL
of	NULL
NF-kB	NULL
p65	NULL
,	NULL
detected	NULL
by	NULL
a	NULL
yellow	NULL
nuclear	NULL
staining	NULL
in	NULL
most	NULL
CTLs	NULL
stimulated	NULL
by	NULL
LAZ509	NULL
only	NULL
,	NULL
whereas	NULL
CTLs	NULL
stimulated	NULL
by	NULL
tumor	NULL
cells	NULL
exhibited	NULL
a	NULL
green	NULL
cytoplasmic	NULL
and	NULL
a	NULL
red	NULL
nuclear	NULL
staining	NULL
,	NULL
indicating	NULL
the	NULL
absence	NULL
of	NULL
nuclear	NULL
translocation	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cytotoxicity	NULL
assays	NULL
indicate	NULL
that	NULL
CTLs	NULL
cultured	NULL
in	NULL
both	NULL
conditions	NULL
display	NULL
similar	NULL
levels	NULL
of	NULL
CD3-redirected	NULL
lysis	NULL
of	NULL
P815	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p58	NULL
triggering	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
tumor	NULL
cell	NULL
stimulation	NULL
of	NULL
p58	NULL
~	NULL
CTLs	NULL
induced	NULL
a	NULL
sustained	NULL
p58-mediated	NULL
inhibition	NULL
of	NULL
the	NULL
lytic	NULL
potential	NULL
,	NULL
and	NULL
inactivation	NULL
of	NULL
NF-kB	NULL
may	NULL
constitute	NULL
one	NULL
possible	NULL
mechanism	NULL
to	NULL
explain	NULL
this	NULL
observation	NULL
.	NULL

Table	NULL
1	NULL
Cytotoxic	NULL
activity	NULL
of	NULL
p38*	NULL
CTL	NULL
2H7	NULL
against	NULL
autologous	NULL
targets	NULL
and	NULL
allogeneic	NULL
normal	NULL
and	NULL
tumor	NULL
cell	NULL
lines	NULL
Lysis	NULL
of	NULL
renal	NULL
tumor	NULL
cells	NULL
was	NULL
tested	NULL
after	NULL
preincubation	NULL
of	NULL
effector	NULL
cells	NULL
with	NULL
anti-p58	NULL
or	NULL
of	NULL
target	NULL
cells	NULL
with	NULL
anti	NULL
HLA-BC	NULL
mAbs	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
lysis	NULL
in	NULL
a	NULL
4-h	NULL
~'Cr	NULL
release	NULL
assay	NULL
(	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
of	NULL
10:1	NULL
)	NULL
.	NULL

One	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

Anti-pS58	NULL
Anti-Cell	NULL
line	NULL
:	NULL
HLA	NULL
Origin	NULL
Medium	NULL
(	NULL
1	NULL
or	NULL
2	NULL
)	NULL
HLA-B/C	NULL
VM	NULL
:	NULL
HLA-A2	NULL
,	NULL
A26	NULL
RCC	NULL
2.3	NULL
325	NULL
VM	NULL
:	NULL
HLA-A2	NULL
,	NULL
A26	NULL
Auto	NULL
PHA-b	NULL
``	NULL
3	NULL
36	NULL
HL	NULL
:	NULL
HLA-A2	NULL
,	NULL
A19	NULL
Allo	NULL
RCC	NULL
32	NULL
62	NULL
50	NULL
LR	NULL
:	NULL
HLA-A2	NULL
,	NULL
A29	NULL
Allo	NULL
RCC	NULL
0	NULL
10	NULL
5	NULL
GB	NULL
:	NULL
HLA-A9	NULL
,	NULL
A32	NULL
Allo	NULL
RCC	NULL
0	NULL
6	NULL
8	NULL
DM	NULL
:	NULL
HLA-A1	NULL
,	NULL
A2	NULL
Allo	NULL
RCC	NULL
5	NULL
17	NULL
CAJE	NULL
:	NULL
HLA-A2	NULL
,	NULL
A26	NULL
Allo	NULL
RCC	NULL
0	NULL
31	NULL
28	NULL
LAZ	NULL
:	NULL
HLA-A2	NULL
,	NULL
A25	NULL
EBV-B	NULL
9	NULL
19	NULL
28	NULL
LCL	NULL
GB	NULL
:	NULL
HLA-A9	NULL
,	NULL
A32	NULL
EBV-B	NULL
11.5	NULL
11	NULL
9.8	NULL
CS	NULL
:	NULL
HLA-A1	NULL
,	NULL
A2	NULL
T	NULL
lymphoma	NULL
16.8	NULL
90	NULL
``	NULL
PHA-b	NULL
,	NULL
PHA	NULL
blasts	NULL
,	NULL
EBV-B	NULL
,	NULL
EBV-transformed	NULL
B	NULL
cells	NULL
.	NULL

*	NULL
Boldface	NULL
represents	NULL
statistically	NULL
increased	NULL
lysis	NULL
percentages	NULL
(	NULL
compared	NULL
to	NULL
medium	NULL
)	NULL
.	NULL

3242	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

SPECIFIC	NULL
T-CELL	NULL
RESPONSE	NULL
IN	NULL
RENAL	NULL
TUMORS	NULL
70	NULL
Md	NULL
anti	NULL
HLA-BC	NULL
Ps	NULL
psa	NULL
anti	NULL
p58.1	NULL
p	NULL
I	NULL
o	NULL
‘	NULL
f	NULL
‘	NULL
v-	NULL
a	NULL
l	NULL
gﬁﬁf	NULL
}	NULL
?	NULL

wae	NULL
HantiCD3	NULL
x	NULL
ao	NULL
Rk	NULL
2p	NULL
30	NULL
yﬁé	NULL
Z	NULL
¥	NULL
V	NULL
p	NULL
13-2	NULL
Txs	NULL
3	NULL
pes	NULL
sh	NULL
10	NULL
R	NULL
R	NULL
,	NULL
Rest	NULL
PRA	NULL
LAZ	NULL
LAZ+TUM	NULL
CD3	NULL
anti	NULL
p58.1	NULL
73	NULL
@	NULL
CD3+	NULL
anti	NULL
p70	NULL
100	NULL
CD3-redirected	NULL
lysis	NULL
i	NULL
z	NULL
<	NULL
4	NULL
Px	NULL
g	NULL
&	NULL
a	NULL
80	NULL
3	NULL
sa	NULL
+	NULL
Fark	NULL
ee	NULL
x	NULL
&	NULL
&	NULL
ras	NULL
X	NULL
R	NULL
sors	NULL
33	NULL
6	NULL
ies	NULL
x	NULL
ar	NULL
#	NULL
$	NULL
5	NULL
e	NULL
<	NULL
3	NULL
e	NULL
,	NULL
$	NULL
&	NULL
3	NULL
&	NULL
3	NULL
3	NULL
>	NULL
3	NULL
e	NULL
o	NULL
<	NULL
X+	NULL
A	NULL
S	NULL
as	NULL
s	NULL
tee	NULL
?	NULL

x	NULL
5	NULL
z	NULL
x	NULL
g	NULL
s	NULL
Re	NULL
it	NULL
&	NULL
x	NULL
$	NULL
iud	NULL
ACC	NULL
LAZ	NULL
+	NULL
TUM	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Modulation	NULL
of	NULL
the	NULL
KIR	NULL
functionality	NULL
expressed	NULL
by	NULL
CTL	NULL
2H7	NULL
upon	NULL
stimulation	NULL
by	NULL
tumor	NULL
cells	NULL
.	NULL

CTL	NULL
2H7	NULL
was	NULL
stimulated	NULL
for	NULL
6	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
LAZ	NULL
509	NULL
(	NULL
LAZ	NULL
)	NULL
or	NULL
LAZS509	NULL
and	NULL
autologous	NULL
tumor	NULL
cells	NULL
(	NULL
10:1	NULL
;	NULL
LAZ+TUM	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
units/ml	NULL
IL-2	NULL
(	NULL
one	NULL
representative	NULL
experiment	NULL
of	NULL
five	NULL
)	NULL
.	NULL

A	NULL
,	NULL
lytic	NULL
activity	NULL
against	NULL
autologous	NULL
tumor	NULL
cells	NULL
.	NULL

Bars	NULL
,	NULL
SE	NULL
.	NULL

B	NULL
,	NULL
CD3-redirected	NULL
lysis	NULL
of	NULL
P815	NULL
mouse	NULL
cells	NULL
in	NULL
presence	NULL
of	NULL
anti-CD3	NULL
.	NULL

Bars	NULL
,	NULL
SE	NULL
.	NULL

C	NULL
,	NULL
activation	NULL
pattern	NULL
of	NULL
NF-kB	NULL
in	NULL
CTL	NULL
2H7	NULL
stimulated	NULL
by	NULL
LAZ509	NULL
(	NULL
LAZ	NULL
)	NULL
or	NULL
LAZS509	NULL
+	NULL
VM	NULL
tumor	NULL
cells	NULL
(	NULL
LAZ+TUM	NULL
)	NULL
.	NULL

Discussion	NULL
Inhibitory	NULL
NK	NULL
receptors	NULL
,	NULL
first	NULL
described	NULL
on	NULL
NK	NULL
cells	NULL
,	NULL
have	NULL
also	NULL
been	NULL
demonstrated	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
normal	NULL
individuals	NULL
,	NULL
small	NULL
subsets	NULL
of	NULL
CD3	NULL
*	NULL
KIR	NULL
*	NULL
cells	NULL
expressing	NULL
a	NULL
memory	NULL
phenotype	NULL
and	NULL
an	NULL
oligoclonal	NULL
TCR	NULL
repertoire	NULL
are	NULL
detected	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
.	NULL

These	NULL
cells	NULL
may	NULL
be	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
chronically	NULL
expressed	NULL
antigens	NULL
(	NULL
11	NULL
)	NULL
,	NULL
possibly	NULL
involved	NULL
in	NULL
the	NULL
maintenance	NULL
of	NULL
tolerance	NULL
or	NULL
prevention	NULL
of	NULL
autoimmunity	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
against	NULL
tumor	NULL
,	NULL
overexpression	NULL
of	NULL
self	NULL
antigens	NULL
may	NULL
induce	NULL
the	NULL
activation	NULL
and	NULL
expansion	NULL
of	NULL
these	NULL
particular	NULL
T	NULL
cells	NULL
at	NULL
the	NULL
tumor	NULL
site	NULL
(	NULL
12	NULL
)	NULL
.	NULL

A	NULL
p58*	NULL
CTL	NULL
that	NULL
recognized	NULL
a	NULL
normal	NULL
tissue-specific	NULL
antigen	NULL
was	NULL
derived	NULL
from	NULL
the	NULL
blood	NULL
of	NULL
a	NULL
metastatic	NULL
melanoma	NULL
patient	NULL
in	NULL
response	NULL
to	NULL
tumor	NULL
cells	NULL
that	NULL
had	NULL
lost	NULL
expression	NULL
of	NULL
a	NULL
complete	NULL
HLA	NULL
haplotype	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
RCC	NULL
,	NULL
we	NULL
previously	NULL
saw	NULL
evidence	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
CD3	NULL
¢	NULL
pS8*	NULL
T	NULL
cells	NULL
infiltrating	NULL
most	NULL
renal	NULL
tumors	NULL
and	NULL
demonstrated	NULL
that	NULL
CTL	NULL
activity	NULL
was	NULL
inhibited	NULL
by	NULL
p58	NULL
receptors	NULL
,	NULL
although	NULL
there	NULL
was	NULL
no	NULL
major	NULL
alteration	NULL
of	NULL
HLA-I	NULL
molecule	NULL
expression	NULL
by	NULL
the	NULL
tumor	NULL
cells	NULL
(	NULL
3	NULL
)	NULL
.	NULL

The	NULL
present	NULL
study	NULL
suggests	NULL
the	NULL
presence	NULL
of	NULL
autoreactive	NULL
T	NULL
cells	NULL
expressing	NULL
an	NULL
inhibitory	NULL
p58	NULL
receptor	NULL
infiltrating	NULL
a	NULL
renal	NULL
tumor	NULL
.	NULL

These	NULL
T	NULL
cells	NULL
display	NULL
a	NULL
memory	NULL
phenotype	NULL
CD45RO	NULL
*	NULL
,	NULL
CD28	NULL
~	NULL
,	NULL
CD56	NULL
*	NULL
,	NULL
and	NULL
correspond	NULL
to	NULL
clonal	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
visualized	NULL
by	NULL
double	NULL
color	NULL
immunolabeling	NULL
using	NULL
anti-BV3	NULL
and	NULL
anti-p58	NULL
mAbs	NULL
in	NULL
the	NULL
uncultured	NULL
TILs	NULL
,	NULL
where	NULL
they	NULL
represented	NULL
1	NULL
%	NULL
of	NULL
CD3	NULL
*	NULL
T	NULL
cells	NULL
but	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
peripheral	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
particular	NULL
pS8*	NULL
T-cell	NULL
subset	NULL
,	NULL
specifically	NULL
expanded	NULL
from	NULL
TILs	NULL
in	NULL
vitro	NULL
,	NULL
corresponds	NULL
to	NULL
the	NULL
main	NULL
tumor-specific	NULL
cytotoxic	NULL
T-cell	NULL
population	NULL
because	NULL
p58~	NULL
T	NULL
cells	NULL
mainly	NULL
mediated	NULL
HLA-unrestricted	NULL
lysis	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
may	NULL
be	NULL
hypothesized	NULL
that	NULL
the	NULL
antigen	NULL
presentation	NULL
by	NULL
tumor	NULL
cells	NULL
and	NULL
tumor	NULL
environment	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
local	NULL
in	NULL
vivo	NULL
expansion	NULL
of	NULL
the	NULL
pS8~	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
in	NULL
peripheral	NULL
blood	NULL
,	NULL
these	NULL
tumor-specific	NULL
p58~*	NULL
CTLs	NULL
are	NULL
efficiently	NULL
regulated	NULL
and	NULL
not	NULL
committed	NULL
to	NULL
proliferate	NULL
.	NULL

Few	NULL
,	NULL
disparate	NULL
data	NULL
are	NULL
yet	NULL
available	NULL
concerning	NULL
the	NULL
regulation	NULL
of	NULL
KIR	NULL
expression	NULL
and	NULL
function	NULL
on	NULL
T	NULL
cells	NULL
,	NULL
mainly	NULL
because	NULL
of	NULL
the	NULL
heterogeneity	NULL
of	NULL
the	NULL
models	NULL
studied	NULL
,	NULL
although	NULL
recent	NULL
studies	NULL
demonstrated	NULL
that	NULL
some	NULL
T	NULL
cells	NULL
acquire	NULL
NK	NULL
marker	NULL
expression	NULL
after	NULL
activation	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
recently	NULL
that	NULL
TCR	NULL
triggering	NULL
restored	NULL
the	NULL
expression	NULL
and	NULL
function	NULL
of	NULL
KIR	NULL
by	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In	NULL
our	NULL
model	NULL
,	NULL
antigen	NULL
presentation	NULL
by	NULL
renal	NULL
tumor	NULL
cells	NULL
does	NULL
influence	NULL
the	NULL
fate	NULL
of	NULL
the	NULL
KIR	NULL
function	NULL
but	NULL
not	NULL
its	NULL
membrane	NULL
expression	NULL
on	NULL
the	NULL
antigen-specific	NULL
T	NULL
cells	NULL
.	NULL

Our	NULL
data	NULL
point	NULL
out	NULL
that	NULL
p58	NULL
receptor	NULL
expression	NULL
does	NULL
not	NULL
necessarily	NULL
correlate	NULL
with	NULL
anergic	NULL
T	NULL
cells	NULL
but	NULL
rather	NULL
modulate	NULL
T-cell	NULL
signaling	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
recently	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
Ly49A	NULL
receptors	NULL
,	NULL
the	NULL
main	NULL
inhibitory	NULL
receptors	NULL
on	NULL
murine	NULL
cells	NULL
,	NULL
enhance	NULL
the	NULL
amounts	NULL
of	NULL
activating	NULL
signals	NULL
required	NULL
for	NULL
effector	NULL
cell	NULL
responses	NULL
and	NULL
that	NULL
inhibition	NULL
of	NULL
Ly49A	NULL
may	NULL
be	NULL
overcome	NULL
by	NULL
increasing	NULL
peptide	NULL
concentration	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Although	NULL
much	NULL
data	NULL
have	NULL
focused	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
NK	NULL
cell	NULL
inhibitory	NULL
receptors	NULL
to	NULL
alter	NULL
T-cell	NULL
activation	NULL
and	NULL
cytotoxicity	NULL
,	NULL
recent	NULL
studies	NULL
using	NULL
KIR	NULL
transgenic	NULL
mouse	NULL
models	NULL
proposed	NULL
that	NULL
NK-R	NULL
expression	NULL
by	NULL
CTLs	NULL
may	NULL
also	NULL
represent	NULL
a	NULL
checkpoint	NULL
in	NULL
T-cell	NULL
activation	NULL
after	NULL
antigen	NULL
stimulation	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
expressing	NULL
KIR	NULL
may	NULL
present	NULL
a	NULL
selective	NULL
advantage	NULL
to	NULL
avoid	NULL
complete	NULL
exhaustion	NULL
by	NULL
over-stimulation	NULL
and	NULL
thus	NULL
may	NULL
correspond	NULL
to	NULL
the	NULL
memory	NULL
cell	NULL
pool	NULL
.	NULL

Our	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
both	NULL
of	NULL
these	NULL
non-mutually	NULL
exclusive	NULL
hypotheses	NULL
because	NULL
although	NULL
we	NULL
demonstrated	NULL
a	NULL
significant	NULL
inhibition	NULL
of	NULL
the	NULL
lytic	NULL
potential	NULL
of	NULL
CTLs	NULL
by	NULL
KIR	NULL
in	NULL
vitro	NULL
,	NULL
this	NULL
receptor	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
proliferation	NULL
or	NULL
the	NULL
survival	NULL
of	NULL
the	NULL
corresponding	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
sustained	NULL
inhibitory	NULL
function	NULL
(	NULL
KIR	NULL
on	NULL
)	NULL
of	NULL
pS58~*	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
tumor	NULL
cells	NULL
was	NULL
correlated	NULL
with	NULL
an	NULL
inhibition	NULL
of	NULL
NF-KB	NULL
activation	NULL
.	NULL

An	NULL
altered	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
in	NULL
TILs	NULL
and	NULL
PBLs	NULL
from	NULL
RCC	NULL
patients	NULL
,	NULL
responsible	NULL
for	NULL
the	NULL
functional	NULL
alterations	NULL
of	NULL
these	NULL
effectors	NULL
(	NULL
20-22	NULL
)	NULL
,	NULL
was	NULL
proposed	NULL
as	NULL
a	NULL
general	NULL
mechanism	NULL
of	NULL
immune	NULL
suppression	NULL
in	NULL
these	NULL
tumors	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
shedding	NULL
of	NULL
gangliosides	NULL
from	NULL
RCC	NULL
cell	NULL
lines	NULL
and	NULL
extracts	NULL
able	NULL
to	NULL
block	NULL
NF-KB	NULL
nuclear	NULL
translocation	NULL
was	NULL
described	NULL
recently	NULL
(	NULL
23	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
NF-KB	NULL
inactivation	NULL
by	NULL
renal	NULL
tumor	NULL
cells	NULL
,	NULL
probably	NULL
independent	NULL
of	NULL
TCR	NULL
stimulation	NULL
,	NULL
is	NULL
induced	NULL
in	NULL
antigen-specific	NULL
CTLs	NULL
.	NULL

Confocal	NULL
analysis	NULL
revealed	NULL
a	NULL
similar	NULL
expression	NULL
of	NULL
granzyme	NULL
B	NULL
and	NULL
perforin	NULL
in	NULL
the	NULL
two	NULL
KIR	NULL
on/KIR	NULL
off	NULL
CTL	NULL
subsets	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
results	NULL
of	NULL
CD3-redirected	NULL
lysis	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
NF-kB	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
lytic	NULL
potential	NULL
of	NULL
CTLs	NULL
by	NULL
a	NULL
mechanism	NULL
independent	NULL
of	NULL
these	NULL
two	NULL
cytotoxic	NULL
gene	NULL
transcrip-tions	NULL
.	NULL

A	NULL
growing	NULL
number	NULL
of	NULL
genes	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
including	NULL
cell	NULL
adhesion	NULL
molecules	NULL
,	NULL
cytokines	NULL
,	NULL
and	NULL
growth	NULL
factors	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Whether	NULL
inhibition	NULL
of	NULL
NF-KB	NULL
activation	NULL
interferes	NULL
with	NULL
some	NULL
structures	NULL
involved	NULL
with	NULL
the	NULL
cytotoxic	NULL
effector	NULL
phase	NULL
in	NULL
our	NULL
model	NULL
has	NULL
to	NULL
be	NULL
investigated	NULL
.	NULL

Alternatively	NULL
,	NULL
it	NULL
is	NULL
known	NULL
that	NULL
KIR	NULL
triggering	NULL
induces	NULL
the	NULL
recruitment	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphatases	NULL
,	NULL
such	NULL
as	NULL
SHP-1	NULL
(	NULL
24	NULL
)	NULL
,	NULL
that	NULL
may	NULL
interfere	NULL
with	NULL
several	NULL
kinases	NULL
required	NULL
3243	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

SPECIFIC	NULL
T-CELL	NULL
RESPONSE	NULL
IN	NULL
RENAL	NULL
TUMORS	NULL
for	NULL
the	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
and	NULL
thus	NULL
blocks	NULL
NF-KB	NULL
activation	NULL
.	NULL

It	NULL
would	NULL
be	NULL
of	NULL
interest	NULL
to	NULL
explore	NULL
the	NULL
possible	NULL
antagonism	NULL
between	NULL
SHP-1	NULL
and	NULL
kinases	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
phosphorylation	NULL
.	NULL

It	NULL
is	NULL
also	NULL
essential	NULL
to	NULL
elucidate	NULL
the	NULL
relationship	NULL
between	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
and	NULL
impairment	NULL
of	NULL
T-cell	NULL
responses	NULL
in	NULL
KIR*	NULL
T	NULL
cells	NULL
to	NULL
get	NULL
more	NULL
insights	NULL
in	NULL
the	NULL
understanding	NULL
of	NULL
the	NULL
function	NULL
of	NULL
NK-R	NULL
in	NULL
vivo	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Yann	NULL
Lécluse	NULL
for	NULL
immunofluorescence	NULL
analyses	NULL
,	NULL
Dr.	NULL
Ryad	NULL
Ta	NULL
mouza	NULL
for	NULL
HLA	NULL
genotyping	NULL
,	NULL
and	NULL
Dr.	NULL
Vladimir	NULL
Lazar	NULL
for	NULL
help	NULL
in	NULL
sequencing	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Bukowski	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Olencki	NULL
,	NULL
T.	NULL
,	NULL
Wang	NULL
,	NULL
Q.	NULL
,	NULL
Peereboom	NULL
,	NULL
D.	NULL
,	NULL
Budd	NULL
,	NULL
G.	NULL
T.	NULL
,	NULL
Elson	NULL
,	NULL
P.	NULL
,	NULL
Sandstrom	NULL
,	NULL
K.	NULL
,	NULL
Tuason	NULL
,	NULL
L.	NULL
,	NULL
Rayman	NULL
,	NULL
P.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
,	NULL
Lain	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Klein	NULL
,	NULL
E.	NULL
,	NULL
Novick	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Finke	NULL
,	NULL
J	NULL
.	NULL

Phase	NULL
II	NULL
trial	NULL
of	NULL
interleukin-2	NULL
and	NULL
interferon-a	NULL
in	NULL
patients	NULL
with	NULL
renal	NULL
cell	NULL
carcinoma	NULL
:	NULL
clinical	NULL
results	NULL
and	NULL
immunologic	NULL
correlates	NULL
responses	NULL
.	NULL

J	NULL
.	NULL

Immunother	NULL
.	NULL

,	NULL
20	NULL
:	NULL
301-311	NULL
,	NULL
1997.	NULL
.	NULL

Alexander	NULL
,	NULL
J.	NULL
,	NULL
Kudoh	NULL
,	NULL
S.	NULL
,	NULL
Melsop	NULL
,	NULL
K.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
,	NULL
Edinger	NULL
,	NULL
M.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
D	NULL
Sica	NULL
,	NULL
L.	NULL
,	NULL
Tuason	NULL
,	NULL
Klein	NULL
,	NULL
E.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Finke	NULL
,	NULL
J.	NULL
T	NULL
cells	NULL
infiltrating	NULL
renal	NULL
cell	NULL
carcinoma	NULL
display	NULL
a	NULL
poor	NULL
proliferative	NULL
response	NULL
even	NULL
though	NULL
they	NULL
can	NULL
produce	NULL
interleukin	NULL
2	NULL
and	NULL
express	NULL
interleukin	NULL
2	NULL
receptors	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
53	NULL
:	NULL
1380-1386	NULL
,	NULL
1993.	NULL
.	NULL

Guerra	NULL
,	NULL
N.	NULL
,	NULL
Guillard	NULL
,	NULL
M.	NULL
,	NULL
Angevin	NULL
,	NULL
E.	NULL
,	NULL
Echchakir	NULL
,	NULL
H.	NULL
,	NULL
Escudier	NULL
,	NULL
B.	NULL
,	NULL
Moretta	NULL
,	NULL
A.	NULL
,	NULL
Chouaib	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Caignard	NULL
,	NULL
A.	NULL
Killer	NULL
inhibitory	NULL
receptor	NULL
(	NULL
CD158b	NULL
)	NULL
modulates	NULL
the	NULL
lytic	NULL
activity	NULL
of	NULL
tumor-specific	NULL
T	NULL
lymphocytes	NULL
infiltrating	NULL
renal	NULL
cell	NULL
carcinomas	NULL
.	NULL

Blood	NULL
,	NULL
95:2883-2889	NULL
,	NULL
2000.	NULL
.	NULL

Moretta	NULL
,	NULL
A.	NULL
,	NULL
Bottino	NULL
,	NULL
C.	NULL
,	NULL
Vitale	NULL
,	NULL
M.	NULL
,	NULL
Pende	NULL
,	NULL
D.	NULL
,	NULL
Biassoni	NULL
,	NULL
R.	NULL
,	NULL
Mingari	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Moretta	NULL
,	NULL
L.	NULL
Receptors	NULL
for	NULL
HLA	NULL
class-I	NULL
molecules	NULL
in	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
14	NULL
:	NULL
619-648	NULL
,	NULL
1996.	NULL
.	NULL

Speiser	NULL
,	NULL
D.	NULL
,	NULL
Valmori	NULL
,	NULL
D.	NULL
,	NULL
Rimoldi	NULL
,	NULL
D.	NULL
,	NULL
Pittet	NULL
,	NULL
M.	NULL
,	NULL
Lienard	NULL
,	NULL
D.	NULL
,	NULL
Cerundolo	NULL
,	NULL
V.	NULL
,	NULL
MacDonald	NULL
,	NULL
H.	NULL
,	NULL
Cerottini	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Romero	NULL
,	NULL
P.	NULL
CD28-negative	NULL
cytolytic	NULL
effector	NULL
T	NULL
cells	NULL
frequently	NULL
express	NULL
NK	NULL
receptors	NULL
and	NULL
are	NULL
present	NULL
at	NULL
variable	NULL
proportions	NULL
in	NULL
circulating	NULL
lymphocytes	NULL
from	NULL
healthy	NULL
donors	NULL
and	NULL
melanoma	NULL
patients	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
29	NULL
:	NULL
1990-1999	NULL
,	NULL
1999.	NULL
.	NULL

Phillips	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Gumperz	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Parham	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Lanier	NULL
,	NULL
L.	NULL
L.	NULL
Superantigen	NULL
dependent	NULL
cell	NULL
mediated	NULL
cytotoxicity	NULL
inhibited	NULL
by	NULL
MHC	NULL
class	NULL
I	NULL
receptors	NULL
on	NULL
T	NULL
lymphocytes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
,	NULL
268	NULL
:	NULL
403-405	NULL
,	NULL
1995.	NULL
.	NULL

D'Andrea	NULL
,	NULL
A.	NULL
,	NULL
Chang	NULL
,	NULL
C.	NULL
,	NULL
Phillips	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Lanier	NULL
,	NULL
L.	NULL
L.	NULL
Regulation	NULL
of	NULL
T	NULL
cell	NULL
lymphokine	NULL
production	NULL
by	NULL
killer	NULL
cell	NULL
inhibitory	NULL
receptor	NULL
recognition	NULL
of	NULL
self	NULL
HLA	NULL
class	NULL
I	NULL
alleles	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
184	NULL
:	NULL
789-794	NULL
,	NULL
1996.	NULL
.	NULL

Caignard	NULL
,	NULL
A.	NULL
,	NULL
Guillard	NULL
,	NULL
M.	NULL
,	NULL
Gaudin	NULL
,	NULL
C.	NULL
,	NULL
Escudier	NULL
,	NULL
B.	NULL
,	NULL
Triebel	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Dietrich	NULL
,	NULL
P.	NULL
In	NULL
situ	NULL
demonstration	NULL
of	NULL
renal	NULL
cell	NULL
carcinoma-specific	NULL
T-cell	NULL
clones	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
66	NULL
:	NULL
564-570	NULL
,	NULL
1996.	NULL
.	NULL

Génévé	NULL
,	NULL
C.	NULL
,	NULL
Diu	NULL
,	NULL
A.	NULL
,	NULL
Nierat	NULL
,	NULL
J.	NULL
,	NULL
Caignard	NULL
,	NULL
A.	NULL
,	NULL
Dietrich	NULL
,	NULL
P.	NULL
Y.	NULL
,	NULL
Ferradini	NULL
,	NULL
L.	NULL
,	NULL
Roman	NULL
Roman	NULL
,	NULL
S.	NULL
,	NULL
Tricbel	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Hercend	NULL
,	NULL
T.	NULL
An	NULL
experimentally	NULL
validated	NULL
panel	NULL
of	NULL
20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

3244	NULL
subfamily	NULL
specific	NULL
oligonucleotide	NULL
primers	NULL
(	NULL
Val-w29/VB1-w24	NULL
)	NULL
for	NULL
the	NULL
study	NULL
of	NULL
human	NULL
T	NULL
cell	NULL
receptor	NULL
variable	NULL
V	NULL
gene	NULL
segment	NULL
usage	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
22	NULL
:	NULL
1261-1269	NULL
,	NULL
1992.	NULL
.	NULL

Hatada	NULL
,	NULL
E.	NULL
,	NULL
Krappmann	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Scheidereit	NULL
,	NULL
C.	NULL
NF-kB	NULL
and	NULL
the	NULL
innate	NULL
immune	NULL
response	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
72	NULL
:	NULL
52-58	NULL
,	NULL
2000.	NULL
.	NULL

Mingari	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Schiavetti	NULL
,	NULL
F.	NULL
,	NULL
Ponte	NULL
,	NULL
M.	NULL
,	NULL
Vitale	NULL
,	NULL
C.	NULL
,	NULL
Maggi	NULL
,	NULL
E.	NULL
,	NULL
Romagnani	NULL
,	NULL
S.	NULL
,	NULL
Demarest	NULL
,	NULL
J.	NULL
,	NULL
Pantaleo	NULL
,	NULL
G.	NULL
,	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
and	NULL
Moretta	NULL
,	NULL
L.	NULL
Human	NULL
CD8+	NULL
T	NULL
lymphocyte	NULL
subsets	NULL
that	NULL
express	NULL
HLA	NULL
class	NULL
I	NULL
specific	NULL
inhibitory	NULL
receptors	NULL
represent	NULL
oligoclonally	NULL
or	NULL
monoclonally	NULL
expanded	NULL
populations	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
;	NULL
12433-12438	NULL
,	NULL
1996.	NULL
.	NULL

Mingari	NULL
,	NULL
M.	NULL
,	NULL
Moretta	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Moretta	NULL
,	NULL
L.	NULL
Regulation	NULL
of	NULL
KIR	NULL
expression	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
:	NULL
a	NULL
safety	NULL
mechanism	NULL
that	NULL
may	NULL
impair	NULL
protective	NULL
T-cell	NULL
responses	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
,	NULL
19:153-157	NULL
,	NULL
1998.	NULL
.	NULL

Ikeda	NULL
,	NULL
H.	NULL
,	NULL
Lethé	NULL
,	NULL
B.	NULL
,	NULL
Lehmann	NULL
,	NULL
F.	NULL
,	NULL
Baren	NULL
,	NULL
N.	NULL
V.	NULL
,	NULL
Baurain	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Smet	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Chambost	NULL
,	NULL
H.	NULL
,	NULL
Vitale	NULL
,	NULL
M.	NULL
,	NULL
Moretta	NULL
,	NULL
A.	NULL
,	NULL
Boon	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Coulie	NULL
,	NULL
P.	NULL
Characterization	NULL
of	NULL
an	NULL
antigen	NULL
that	NULL
is	NULL
recognized	NULL
on	NULL
a	NULL
melanoma	NULL
showing	NULL
partial	NULL
HLA	NULL
loss	NULL
by	NULL
CTL	NULL
expressing	NULL
an	NULL
NK	NULL
inhibitory	NULL
receptor	NULL
.	NULL

Immunity	NULL
,	NULL
6	NULL
:	NULL
199-208	NULL
,	NULL
1997.	NULL
.	NULL

Coles	NULL
,	NULL
M.	NULL
,	NULL
McMahon	NULL
,	NULL
C.	NULL
,	NULL
Takizawa	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Raulet	NULL
,	NULL
D.	NULL
Memory	NULL
CD8	NULL
T	NULL
lymphocytes	NULL
express	NULL
inhibitory	NULL
MHC-specific	NULL
Ly49	NULL
receptors	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
30	NULL
:	NULL
236-244	NULL
,	NULL
2000.	NULL
.	NULL

Slifka	NULL
,	NULL
M.	NULL
,	NULL
Pagarigan	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Whitton	NULL
,	NULL
J.	NULL
NK	NULL
markers	NULL
are	NULL
expressed	NULL
on	NULL
a	NULL
high	NULL
percentage	NULL
of	NULL
virus-specific	NULL
CD8+	NULL
and	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
164	NULL
:	NULL
2009-2015	NULL
,	NULL
2000.	NULL
.	NULL

Huard	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Karlsson	NULL
,	NULL
L.	NULL
KIR	NULL
expression	NULL
on	NULL
self-reactive	NULL
CD8+	NULL
T	NULL
cells	NULL
is	NULL
controlled	NULL
by	NULL
T-cell	NULL
receptor	NULL
engagement	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
403	NULL
:	NULL
325-328	NULL
,	NULL
2000.	NULL
.	NULL

Oberg	NULL
,	NULL
L.	NULL
,	NULL
Eriksson	NULL
,	NULL
M.	NULL
,	NULL
Fahlen	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Sentman	NULL
,	NULL
C.	NULL
Expression	NULL
of	NULL
Ly49A	NULL
on	NULL
T	NULL
cells	NULL
alters	NULL
the	NULL
threshold	NULL
for	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
30	NULL
:	NULL
2849-2856	NULL
,	NULL
2000.	NULL
.	NULL

Cambiaggi	NULL
,	NULL
A.	NULL
,	NULL
Darche	NULL
,	NULL
S.	NULL
,	NULL
Guia	NULL
,	NULL
S.	NULL
,	NULL
Kourilsky	NULL
,	NULL
P.	NULL
,	NULL
Abastado	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Vivier	NULL
,	NULL
E.	NULL
Modulation	NULL
of	NULL
T	NULL
cell	NULL
functions	NULL
in	NULL
KIR2DL3	NULL
(	NULL
CD158b	NULL
)	NULL
transgenic	NULL
mice	NULL
.	NULL

Blood	NULL
,	NULL
94	NULL
:	NULL
2396-2402	NULL
,	NULL
1999.	NULL
.	NULL

Ugolini	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Vivier	NULL
,	NULL
E.	NULL
Regulation	NULL
of	NULL
T	NULL
cell	NULL
function	NULL
by	NULL
NK	NULL
cell	NULL
receptors	NULL
for	NULL
classical	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
72	NULL
;	NULL
295-300	NULL
,	NULL
2000	NULL
.	NULL

Li	NULL
,	NULL
X.	NULL
,	NULL
Liu	NULL
,	NULL
J.	NULL
,	NULL
Park	NULL
,	NULL
J.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
,	NULL
Rayman	NULL
,	NULL
P.	NULL
,	NULL
Klein	NULL
,	NULL
E.	NULL
,	NULL
Edinger	NULL
,	NULL
M.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Finke	NULL
,	NULL
J.	NULL
T	NULL
cells	NULL
from	NULL
renal	NULL
cell	NULL
carcinoma	NULL
patients	NULL
exhibit	NULL
an	NULL
abnormal	NULL
pattern	NULL
of	NULL
xB-specific	NULL
DNA-binding	NULL
activity	NULL
:	NULL
a	NULL
preliminary	NULL
report	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
54	NULL
:	NULL
5424-5429	NULL
,	NULL
1994	NULL
.	NULL

Ling	NULL
,	NULL
W.	NULL
,	NULL
Rayman	NULL
,	NULL
P.	NULL
,	NULL
Uzzo	NULL
,	NULL
R.	NULL
,	NULL
Clark	NULL
,	NULL
P.	NULL
,	NULL
Kim	NULL
,	NULL
H.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
,	NULL
Novick	NULL
,	NULL
A.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Finke	NULL
,	NULL
J	NULL
.	NULL

Impaired	NULL
activation	NULL
of	NULL
NFkB	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
a	NULL
subset	NULL
of	NULL
renal	NULL
cell	NULL
carcinoma	NULL
patients	NULL
is	NULL
mediated	NULL
by	NULL
inhibition	NULL
of	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
the	NULL
inhibitor	NULL
,	NULL
IkBa	NULL
.	NULL

Blood	NULL
,	NULL
92	NULL
:	NULL
1334-1341	NULL
,	NULL
1998	NULL
.	NULL

Uzzo	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
Clark	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
Rayman	NULL
,	NULL
P.	NULL
,	NULL
Bloom	NULL
,	NULL
T.	NULL
,	NULL
Rybicki	NULL
,	NULL
L.	NULL
,	NULL
Novick	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Finke	NULL
,	NULL
J.	NULL
H.	NULL
Alterations	NULL
in	NULL
NFKB	NULL
activation	NULL
in	NULL
T	NULL
lymphocytes	NULL
of	NULL
patients	NULL
with	NULL
renal	NULL
cell	NULL
carcinoma	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

,	NULL
97	NULL
:	NULL
718-721	NULL
,	NULL
1999	NULL
.	NULL

Uzzo	NULL
,	NULL
R.	NULL
,	NULL
Rayman	NULL
,	NULL
P.	NULL
,	NULL
Kolenko	NULL
,	NULL
V.	NULL
,	NULL
Clark	NULL
,	NULL
P.	NULL
,	NULL
Cathcart	NULL
,	NULL
M.	NULL
,	NULL
Bloom	NULL
,	NULL
T.	NULL
,	NULL
Novick	NULL
,	NULL
A.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Finke	NULL
,	NULL
J.	NULL
Renal	NULL
cell	NULL
carcinoma-derived	NULL
gangliosides	NULL
suppress	NULL
nuclear	NULL
factor-kB	NULL
activation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Investig	NULL
.	NULL

,	NULL
104	NULL
:	NULL
769-776	NULL
,	NULL
1999	NULL
.	NULL

Blery	NULL
,	NULL
M.	NULL
,	NULL
Olcese	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Vivier	NULL
,	NULL
E.	NULL
Early	NULL
signaling	NULL
via	NULL
inhibitory	NULL
and	NULL
activating	NULL
NK	NULL
receptors	NULL
.	NULL

Hum	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
67:51-64	NULL
,	NULL
2000	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAC	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Tumor	NULL
Cells	NULL
Regulate	NULL
the	NULL
Lytic	NULL
Activity	NULL
of	NULL
Tumor-specific	NULL
Cytotoxic	NULL
T	NULL
Lymphocytes	NULL
by	NULL
Modulating	NULL
the	NULL
Inhibitory	NULL
Natural	NULL
Killer	NULL
Receptor	NULL
Function	NULL
Asma	NULL
Gati	NULL
,	NULL
Nadia	NULL
Guerra	NULL
,	NULL
Julien	NULL
Giron-Michel	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
2001	NULL
Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/61/8/3240	NULL
Cited	NULL
articles	NULL
Citing	NULL
articles	NULL
This	NULL
article	NULL
cites	NULL
23	NULL
articles	NULL
,	NULL
9	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/61/8/3240	NULL
full	NULL
#	NULL
ref-list-1	NULL
This	NULL
article	NULL
has	NULL
been	NULL
cited	NULL
by	NULL
5	NULL
HighWire-hosted	NULL
articles	NULL
.	NULL

Access	NULL
the	NULL
articles	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/61/8/3240	NULL
full	NULL
#	NULL
related-urls	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/61/8/3240	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

